home / stock / pnexf / pnexf news
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
French biotech Pharnext ( OTC:PNEXF ) appointed Rob Quinn as CFO, effective immediately. Quinn replaces Valérie Worrall, who stepped down to pursue other interests, the company said in a Sept. 1 press release. Quinn recently served as CFO of Benevol...
Pharnext ( OTC:PNEXF ) said it signed a €2.5M loan agreement with French biotech Néovacs. The loan will bear interest at 1% per month for a maximum duration of six months (until Feb. 21, 2023 at the latest). France-based Pharnext added that the ex...
PARIS, FRANCE / ACCESSWIRE / March 31, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PL...
€6 million capital raise priced at market with warrants subscribed by two existing shareholders, €5 million convertible bonds issued to European investors, European investors have also provided written indication of strong interest for the potential of additional ...
Pharnext SA ( OTCPK:PNEXF ): FY net loss of €23.3M Cash and cash equivalents of €16.25M Press Release More news on: Pharnext SA, Earnings news and commentary, ,
Pharnext SA ( OTCPK:PNEXF ): 1H Net loss of €12.29M. More news on: Pharnext SA, Earnings news and commentary, , Read more ...
The FDA has recommended Pharnext SA ( OTCPK:PNEXF ) to conduct an additional Phase 3 study to evaluate PXT3003 in Charcot-Marie-Tooth Disease Type 1A ("CMT1A"). More news on: Pharnext SA, Healthcare stocks news, Read more ...
Pharnext SA ( OTCPK:PNEXF ): Q1 net loss of €21.3M More news on: Pharnext SA, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pharnext SA Company Name:
PNEXF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE / ACCESSWIRE / January 4, 2023 / Pharnext SA (FR001400BV89:ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson a...
PARIS, FRANCE / ACCESSWIRE / March 31, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PL...
€6 million capital raise priced at market with warrants subscribed by two existing shareholders, €5 million convertible bonds issued to European investors, European investors have also provided written indication of strong interest for the potential of additional ...